Bolt Biotherapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William Quinn
- Full Time Employees
- 52
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 900 Chesapeake Drive Redwood City CA United States of America 94063
- IPO Date
- Feb 5, 2021
- CIK
- 0001641281
- Website
- boltbio.com
- Similar Companies
- Business
- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) is a clinical-stage biotechnology company that develops novel immunotherapies to harness the innate immune system against cancer by leveraging its proprietary Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform and expertise in myeloid biology. The company offers BDC-3042, a first-in-class Dectin-2 agonist antibody that repolarizes tumor-associated macrophages from tumor-supportive to tumor-destructive states for non-small cell lung cancer, melanoma, and other solid tumors currently in Phase 1 with clinical data anticipated in the second quarter of 2025; BDC-4182, a next-generation claudin 18.2-targeted ISAC for gastric, gastroesophageal junction, pancreatic, and other cancers with a Phase 1 dose-escalation trial ongoing; preclinical CEA (CEACAM5)-targeted ISAC for colorectal and non-small cell lung cancers; preclinical PD-L1-targeted ISAC for solid tumors; and additional bispecific ISACs funded through early clinical development, including a Caprin-1-targeted ISAC. Bolt maintains strategic collaborations with Genmab to advance multiple next-generation ISAC programs and with Toray Industries to combine its immunostimulatory linker-payloads with Toray's Caprin-1 antibodies for solid tumors; it seeks partners for BDC-3042 following Phase 1 completion, completed a 1:20 reverse stock split in June 2025 to regain Nasdaq compliance, and reported third quarter 2025 financial results with ongoing progress in collaborations and pipeline milestones. Founded in 2015 by Dr. Edgar G. Engleman of Stanford University and headquartered at 900 Chesapeake Drive in Redwood City, California, in the San Francisco Bay Area, Bolt targets unmet needs in immuno-oncology across solid tumor patient populations primarily in the United States.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Grows By 355.3%
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics (NASDAQ:BOLT) versus Nkarta (NASDAQ:NKTX) Head to Head Review
Bolt Biotherapeutics to Participate in Upcoming March Conferences
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 83.8% in December
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus Bolt Biotherapeutics (NASDAQ:BOLT)
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
CSE Bulletin: Consolidation - Bolt Metals Corp. (BOLT)
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Squarepoint Ops LLC Buys New Holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025